Recently, Eli Lilly started a phase Ib/2 clinical trial for pancreatic cancer patients with Gemcitabine and LY2157299, an imidazole derivative inhibitor of TβRI ATP-binding pocket (ClinicalTrials.gov identifier: NCT01373164). This evidence concerns the gene TGFBR1 and familial pancreatic carcinoma.